title: FibroScan, APRI, FIB4, and GUCI: Role in prediction of fibrosis and response to therapy in Egyptian patients with HCV infection.
abstract: OBJECTIVE
  Multiple noninvasive methods have been used successfully in the prediction of fibrosis. However, their role in the prediction of response to hepatitis C virus (HCV) antiviral therapy is debatable. The aim of this study was to validate and compare the diagnostic performance of FibroScan, APRI (aspartate aminotransferase (AST)-to-platelet ratio index), FIB4, and GUCI (Göteborg University Cirrhosis Index) for the prediction of hepatic fibrosis and treatment outcome in HCV-infected patients receiving pegylated interferon and ribavirin (PEG-IFN/ribavirin).
  
  
  METHODS
  This study included 182 Egyptian patients with chronic HCV infection. They were classified into two groups based on the stages of fibrosis: mild to significant fibrosis (F1-F2) and advanced fibrosis (F3-F4). The APRI, FIB4, and GUCI scores were calculated before the antiviral treatment. The FibroScan was performed for all patients before treatment.
  
  
  RESULTS
  Stiffness and FIB4 have greater sensitivity and specificity in detecting advanced fibrosis of 80%, 77% and 88%, 84%, respectively. Based on multivariate regression analysis, FIB4, body mass index (BMI), and alpha-fetoprotein (AFP) level were found to be statistically significant predictors of advanced fibrosis (p-value: 0.000, 0.011, and 0.001, respectively) with odds ratio (OR: 3.184, 1.170, and 1.241, respectively). With respect to virological response, the stiffness, APRI, FIB4, and GUCI were significantly lower in sustained virological responders. However, these are not good predictors of response to PEG-IFN/ribavirin therapy. AFP was the only statistically significant predictor of response (p=0.002) with OR of 1.141 in multivariate regression analysis.
  
  
  CONCLUSIONS
  FibroScan and noninvasive scores such as APRI, FIB4, and GUCI can be used as good predictors of liver fibrosis in chronic hepatitis C. However, they are not good predictors of response to PEG-IFN/ribavirin therapy.
authors.affiliation: Endemic Medicine and Hepatology Department, Faculty of Medicine, Cairo University, Cairo, Egypt.
authors.forename: Ayman
authors.initials: A
authors.lastname: Yosry
authors.affiliation: Endemic Medicine and Hepatology Department, Faculty of Medicine, Cairo University, Cairo, Egypt.
authors.forename: Rabab
authors.initials: R
authors.lastname: Fouad
authors.affiliation: Endemic Medicine and Hepatology Department, Faculty of Medicine, Cairo University, Cairo, Egypt. Electronic address: shery_2424@yahoo.com.
authors.forename: Shereen A
authors.initials: SA
authors.lastname: Alem
authors.affiliation: Endemic Medicine and Hepatology Department, Faculty of Medicine, Cairo University, Cairo, Egypt.
authors.forename: Aisha
authors.initials: A
authors.lastname: Elsharkawy
authors.affiliation: Endemic Medicine and Hepatology Department, Faculty of Medicine, Cairo University, Cairo, Egypt.
authors.forename: Mohammad
authors.initials: M
authors.lastname: El-Sayed
authors.affiliation: Public Health Department, Faculty of Medicine, Cairo University, Cairo, Egypt.
authors.forename: Noha
authors.initials: N
authors.lastname: Asem
authors.affiliation: Pathology Department, National Hepatology and Tropical Medicine Research Institute (NHTMRI), Cairo, Egypt.
authors.forename: Ehsan
authors.initials: E
authors.lastname: Hassan
authors.affiliation: Hepatology Department, National Hepatology and Tropical Medicine Research Institute (NHTMRI), Cairo, Egypt.
authors.forename: Ahmed
authors.initials: A
authors.lastname: Ismail
authors.affiliation: Endemic Medicine and Hepatology Department, Faculty of Medicine, Cairo University, Cairo, Egypt.
authors.forename: Gamal
authors.initials: G
authors.lastname: Esmat
mesh_terms: D000328:Adult; D000410:Alanine Transaminase / Q000097:blood; D000998:Antiviral Agents / Q000627:therapeutic use*; D019540:Area Under Curve; D001219:Aspartate Aminotransferases / Q000097:blood; D004359:Drug Therapy, Combination; D004534:Egypt; D054459:Elasticity Imaging Techniques; D005260:Female; D019698:Hepatitis C, Chronic / Q000150:complications / Q000188:drug therapy*; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000627:therapeutic use*; D019934:International Normalized Ratio; D008103:Liver Cirrhosis / Q000097:blood* / Q000000981:diagnostic imaging* / Q000473:pathology / Q000821:virology; D008297:Male; D008875:Middle Aged; D010976:Platelet Count; D011092:Polyethylene Glycols / Q000627:therapeutic use*; D011237:Predictive Value of Tests; D012372:ROC Curve; D011994:Recombinant Proteins / Q000627:therapeutic use; D012254:Ribavirin / Q000627:therapeutic use*
chemical_list: D000998:Antiviral Agents; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D011092:Polyethylene Glycols; D012254:Ribavirin; D001219:Aspartate Aminotransferases; D000410:Alanine Transaminase; C417083:peginterferon alfa-2b
keywords: Aspartate aminotransferase-to-platelet ratio index; Chronic hepatitis C virus; FIB4; FibroScan; Göteborg University Cirrhosis Index